Get the Stockscreener App
7.35
0.96%
0.07
After Hours:
7.25
-0.10
-1.36%
Arcturus Therapeutics Holdings Inc stock is traded at $7.35, with a volume of 549.46K.
It is up +0.96% in the last 24 hours and up +0.68% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$7.28
Open:
$7.24
24h Volume:
549.46K
Relative Volume:
1.28
Market Cap:
$208.91M
Revenue:
$67.22M
Net Income/Loss:
$-65.78M
P/E Ratio:
-3.0796
EPS:
-2.3867
Net Cash Flow:
$-79.02M
1W Performance:
+7.77%
1M Performance:
+0.68%
6M Performance:
+11.20%
1Y Performance:
-46.66%
1-Day Range:
$7.13
$7.66
1-Week Range:
$6.69
$8.28
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.35 | 191.00M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | B. Riley Securities | Buy |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus partners with Thermo Fisher for cystic fibrosis drug - Investing.com
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Business Wire
Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Enterprise value to EBIT forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT) - TradingView
ARCT Forecast — Price Target — Prediction for 2027 - TradingView
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Discipline and Rules-Based Execution in ARCT Response - Stock Traders Daily
ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ARCT Q1 2026 Earnings: Narrower-than-expected loss highlights clinical momentumMid-Term Outlook - newsline.com
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Institutional Confidence - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arcturus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HOLMES EDWARD W - Moomoo
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant - Stock Titan
Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options - Stock Titan
Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant - Stock Titan
Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30 - Stock Titan
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant - Stock Titan
Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options - Stock Titan
Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options - Stock Titan
Arcturus Therapeutics highlights mRNA pipeline, CF data and vaccine expansion at Jefferies - MSN
ARCT Q1 2026 Earnings: Narrower-than-Expected Loss Despite No RevenueProfit Margin Analysis - Město Břeclav
Behavioral Patterns of ARCT and Institutional Flows - Stock Traders Daily
mRNA Vaccines and Therapeutics Market Size, Share, Growth, 2034 - Straits Research
Arcturus Therapeutics Holdings Inc. 2026 Annual Shareholder Meeting Results and Election of Directors - Minichart
Arcturus Shareholders Back Board, Pay, and Auditor - TipRanks
Arcturus Therapeutics (ARCT) holders elect board, approve pay and auditor - Stock Titan
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies - inkl
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next - Bez Kabli
Arcturus Therapeutics Holds Steady at $7.92 as Market Awaits CatalystsMomentum ETF - newsline.com
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Arcturus Therapeutics Poised for a Massive Upside in 2026 - Kavout
Arcturus Therapeutics (ARCT) Holds Steady at $7.92 – Waiting for a CatalystTriple EMA - newsline.com
Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026 - Traders Union
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Arcturus Therapeutics (ARCT) Surges 6.2% as Buyers Defend Key SupportFibonacci Extension - thelegaladvocate.com
Arcturus Therapeutics urges new solutions as 10 percent of cystic fibrosis patients still lack effective treatment - Traders Union
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):